BioSig Technologies, a leading medical technology company specializing in intracardiac signal visualization, announced a significant milestone today with the reception of multiple new utility patents from the U.S. Patent and Trademark Office. These patents pertain to the Company’s cutting-edge PURE EP digital signal processing technology. As a result of this development, Biosig Technologies’ stock has experienced a substantial surge in value.
At the time of this publication, BioSig Technologies Inc stock (BSGM) has witnessed a surge.
BioSig Technologies Inc
Current Price: $0.47
Change : +0.13
Change (%): (36.36%)
Volume: 950.9K
Source: Tomorrow Events Market Data
Kenneth Londoner, the Chairman and CEO of BioSig, expressed his satisfaction with the achievement, stating, “We are pleased to add five utility patent awards to our expanding intellectual property portfolio of more than 100 patents and patent applications in the U.S. and abroad. Our robust patent protection and well-constructed claims cover BioSig’s first mover advantage for our novel PURE EP Platform.”
The newly awarded patents include:
– U.S. Patent Application No. 16/543,061, which received approval on September 22, 2023. This patent focuses on “Systems and Methods To Display Cardiac Signals Based on a Signal Pattern.” It outlines a computer-based method for visualizing cardiac signals in a pattern-matching format, displayed side by side and vertically stacked.
– U.S. Patent No. 11,737,699, granted on August 29, 2023, titled “Systems and Methods for Performing Electrophysiology (EP) Signal Processing.” This patent outlines methods and systems for generating a clean unipolar signal.
– U.S. Patent No. 11,737,701, also granted on August 29, 2023, entitled “Methods, Systems and Media For Reconstructing Bioelectric Lead Placement.” It describes methods and systems employing artificial intelligence for reconstructing electrode placement on a patient.
– U.S. Patent 11,617,529, granted on April 4, 2023, titled “Apparatus and Methods for Removing a Large-Signal Voltage Offset from a Biomedical Signal.” This patent claims a method for processing an electrical signal afflicted with a substantial differential voltage offset.
– U.S. Patent 11,617,530, granted on April 4, 2023, also entitled “Apparatus and Methods for Removing a Large-Signal Voltage Offset from a Biomedical Signal.” This patent focuses on a system designed for the removal of noise in electrocardiogram (ECG) and intracardiac (IC) signals.
BioSig’s patent portfolio now includes:
– 35 issued and allowed utility patents
– 30 issued design patents worldwide
– 23 U.S. and foreign utility patent applications in various stages of approval, covering different aspects of the PURE EP Platform
– 1 allowed and 1 pending U.S. patent application centered on artificial intelligence (AI)
– Licenses secured for 11 patents and an additional 9 worldwide utility patent applications pending from Mayo Foundation for Medical Education and Research.
The PURE EP™ Platform revolutionizes the practice of physicians by enabling the real-time acquisition of unadulterated cardiac signal data, devoid of extraneous noise or interference commonly encountered in conventional approaches.
